After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Protagonist Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Protagonist Therapeutics Inc is $5.64B. A total of 1.38 million shares were traded on the day, compared to an average of 1.18M shares.
In the most recent transaction, MOLINA ARTURO MD sold 2,712 shares of PTGX for 84.77 per share on Nov 17 ’25. After the transaction, the Chief Medical Officer now owns 81,180 company shares. In a previous transaction on Oct 10 ’25, Waddill William D. sold 12,000 shares at 81.62 per share. PTGX shares that Director owns now total 5,130.
Among the insiders who bought shares, WILLIAM WADDILL acquired of 12,000 shares on Oct 10 ’25 at a per-share price of $67.04. In another insider transaction, Waddill William D. sold 4,000 shares at $64.25 per share on Sep 22 ’25. Company shares held by the Director now total 5,130.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, PTGX has a high of $93.25 and a low of $33.70.
As of this writing, PTGX has an earnings estimate of -$0.56 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of $0.09 per share and a lower estimate of -$0.78. The company reported an EPS of $1.98 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. PTGX’s latest balance sheet shows that the firm has $326.90M in Cash & Short Term Investments as of fiscal 2021. There were $5.86M in debt and $44.02M in liabilities at the time. Its Book Value Per Share was $10.34, while its Total Shareholder’s Equity was $300.02M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PTGX is Buy with a score of 4.71.
